GlobeNewswire Inc. · May 12, 2023
Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update
Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022
IM
NASDAQ · IMPL
Impel Pharmaceuticals Inc.
Healthcare · Biotechnology
$0.04
Down-$0.02 (-27.27%)
Updated Aug 14, 2026, 7:23 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 956K
- P/E ratio
- -0.01
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 720.03K
- Avg. volume
- 1.05M
Price performance
IMPL price history
1M range · 0 trading sessions · Daily adjusted prices
IMPL does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest IMPL news
The latest Smart Investors Daily articles mentioning IMPL.
Stock researchCompany · Overview
IMPL research
Overview
Company profile and research snapshot.
Company profile
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 15, 2022 | Wedbush | Neutral | — |
| Aug 25, 2022 | JonesTrading | Buy | — |
| May 18, 2021 | Guggenheim | Buy | — |
| May 18, 2021 | Wedbush | Outperform | — |
News briefing
No generated briefing is available yet.
GlobeNewswire Inc. · May 5, 2023
Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023
SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m. ET to report its first quarter 2023 financial results and provide a business update.
GlobeNewswire Inc. · Apr 26, 2023
Impel Pharmaceuticals Presents New Data at AAN 2023 Suggesting Trudhesa® Nasal Spray is Safe to Use When Co-Administered With Commonly Prescribed Migraine Medications
New Analysis Indicates No Drug-Drug Interactions (DDIs) of Clinical Concern are Predicted When Recommended Doses of Trudhesa and Gepants are Co-Administered
GlobeNewswire Inc. · Apr 12, 2023
Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of Directors
H. Stewart Parker Departing from Board H. Stewart Parker Departing from Board
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
